Study S000551

Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus With Metabolic Dysfunction-associated Steatotic Liver Disease: A Randomized Controlled Trial

ClinicalTrials.gov record

Registration

Registration: NCT07274644
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 36
Start: 2025-03-29
Primary completion: 2026-06-30
Lead sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus Type 2
Interventions: DRUG:iGlarLixi; DRUG:IGlar U100
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Absolute change from baseline to Week 12 in hepatic fat fraction [Baseline, Week 12]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.